skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Nuclear medicine progress report for quarter ending September 30, 1985

Technical Report ·
DOI:https://doi.org/10.2172/6234664· OSTI ID:6234664

A new dimethyl-branched fatty acid analogue has been developed with radioiodide stabilized as an iodovinyl moiety at the terminus of the fatty acid chain. The new radioiodinated terminal iodovinyl-3,3-dimethyl-branched fatty acid showed higher myocardial uptake (4.56% dose/gm at 2 min), longer myocardial retention (4.10% dose/gm at 60 min), lower blood levels (0.71% dose/gm at 60 min), and higher heart:blood ratios (5.8:1 at 60 min) in fasted Fischer rats than observed with the corresponding monomethyl analogue. The subcellular distribution and lipid analysis studies of a series of iodovinyl fatty acids which include the straight chain parent, 19-iodo-18-nonadecenoic acid (IVN), monomethyl-branched analogue, 19-iodo-3-(R,S)-methyl-18-nonadecenoic acid (BMIVN), and the dimethyl-branched analogue, 19-iodo-3,3-dimethyl-18-nonadecenoic acid (DMIVN), are described. 4 refs., 3 figs., 3 tabs.

Research Organization:
Oak Ridge National Lab. (ORNL), Oak Ridge, TN (United States)
DOE Contract Number:
AC05-84OR21400
OSTI ID:
6234664
Report Number(s):
ORNL/TM-9784; ON: DE86006751
Resource Relation:
Other Information: Portions of this document are illegible in microfiche products. Original copy available until stock is exhausted
Country of Publication:
United States
Language:
English

Similar Records